The Onetouch® Ping® Insulin Pump and Meter-Remote

Performance-powered. The OneTouch ® Ping ® insulin pump and meter-remote.

We don’t just deliver insulin.

We deliver outstanding clinical performance.

P36337_OTP_DetAid_OmniPodUpdate_r12.indd 1 10/25/13 5:49 PM OneTouch ® Ping.® Where clinical performance meets lifestyle performance.

5 big advantages of pump therapy 8 big advantages of OneTouch ® Ping.® compared with multiple daily injections.

OneTouch ® Ultra® Blue Test Strips have DoubleSure™ Technology, 1 Lower HbA1c levels1-4 which automatically checks each blood sample twice to confirm the result 2 Reduced glycemic variability3,5 Significantly better 3 Reduced severe hypoglycemia2-4,6,7 accuracy per basal Superior bolus delivery calculator* vs. Medtronic,† Roche, 4 Fewer daily injections at achieving and Next-Generation ® Fine-tuned control OmniPod in a study postprandial control with the only insulin vs. the Medtronic comparing dose-to- ‡ pump to deliver basal ®8 dose variability 5 More flexibility Bolus Wizard insulin in 0.025 U/hr increments across all available rates (0.025 U/hr–25 U/hr)

The majority of people who change to an insulin pump don’t go back to injections.1

Discreet diabetes management with remote bolus

Uninterrupted insulin delivery with waterproof pump§

Accurate carb Outstanding counting readability via built-in for patients CalorieKing™ with low food database vision9

*Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator. The bolus calculator in the Medtronic MiniMed® 530G pump is unchanged from the bolus calculator in the Paradigm® Revel™ pump. †The Medtronic MiniMed® 530G pump is unchanged from the Paradigm® Revel™ pump with the exception of the added Threshold Suspend tool, and some minor software differences. ‡Bench data: Jahn LG, Capurro JJ, Levy BL. Comparative dose accuracy of durable and patch insulin infusion pumps. J Diabetes Sci Technol. 2013;7(4):1011-1020. (Study conducted using OneTouch ® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®.) Capurro J, Levy B. Dose accuracy comparison between Animas OneTouch® Ping®, Insulet OmniPod®, and Next-Generation OmniPod®. Abstract and poster presented at: Diabetes Technology Society Meeting; October 31- November 2, 2013; San Francisco, CA. §The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.

P36337_OTP_DetAid_OmniPodUpdate_r12.indd 2-3 10/25/13 5:49 PM 220 Hyperglycemia 200 150

180 189.2 mg/dL 100 160 157.4 mg/dL 158.2 mg/dL mean blood glucose 140 50 8* Not all bolus calculators127.3 mg/dL are created125.6 mg/dL equal. 120 mean blood glucose ...... 0 100 96.4 mg/dL -50 80 ® 8† Our bolus calculator is superior at achieving postprandial control versus-100 the Medtronic Bolus Wizard. 60 Hypoglycemia The MiniMed® 530G bolus calculator is unchanged from the Paradigm® Revel™ bolus calculator. 40 -150 0 5 10 15 20 In a clinical study, the automated bolus calculator used in OneTouch® Ping® was shown to be The automated bolus calculator used in OneTouch® Ping® more efficacious in controlling postprandial hyperglycemia than the Medtronic Bolus Wizard®.8* recommended a correction insulin bolus significantly more frequently The postprandial target range for this study was set at 80 mg/dL to 140 mg/dL. than the Medtronic Bolus Wizard® (P=.0002).8*

90 Proximity to target 6 hours post-meal Time within target blood glucose range 80 (44-hour study interval)

220 70 • Postprandial blood glucose levels were 20 • Patients using the bolus significantly closer to target among calculator in OneTouch® Ping® Hyperglycemia 60 patients using the bolus calculator in 4.7 hours longer remained within the target 200 ® ® OneTouch Ping than among patients range significantly longer than ® 189.2 mg/dL50 using the Medtronic Bolus Wizard those using the Medtronic 180 (17.3 ± 30.9 mg/dL vs. 47.4 ± 31.8 mg/dL, 15 19.9 h Bolus Wizard® in a clinical 8 8 40 respectively) * P=.0363 study (P=.0363) * 160 157.4 mg/dL 158.2 mg/dL 30 mean blood glucose P=.0363 15.2 h

140 Hours 10 20 127.3 mg/dL 125.6 mg/dL 120 mean blood glucose 10

...... 110 mg/dL target0 midpoint 5 100 96.4 mg/dL ±5 ±10 ±20 ±30 ±40 ±50 80 Target RangeTarget (mg/dL) 0 60 Hypoglycemia OneTouch ® Ping® Medtronic bolus calculator Bolus Wizard® 40 144 ± 50.7 mg/dL 162.3 ± 49.6 mg/dL OneTouch ® Ping® Medtronic mean blood glucose mean blood glucose bolus calculator Bolus Wizard® corrected to 110 mg/dL corrected to 140 mg/dL (midpoint of target) (upper limit of target)

Automated bolus calculator technology that excels. The bolus calculator in OneTouch® Ping® corrects to the midpoint of the programmed target blood glucose range. The Medtronic Bolus

® ® Wizard corrects to the outer limits of the target. This can impact *Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas 2020, MiniMed Paradigm , and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator. The bolus calculator in the Medtronic MiniMed® 530G pump is unchanged from the bolus calculator the amount of insulin recommended and whether or not a correction in the Paradigm® Revel™ pump. †Medtronic Bolus Wizard® feature information from Medtronic MiniMed Paradigm® Revel™ and 530G User Guides and Zisser H, Wagner R, Pleus S, et al. Diabetes Technol Ther. 2010;12(12):955-961. is recommended. 8†

P36337_OTP_DetAid_OmniPodUpdate_r12.indd 4-5 10/25/13 5:49 PM Not all basal insulin delivery is created equal.*

OneTouch ® Ping® demonstrates superior accuracy per delivery of basal insulin versus Medtronic,†‡ Roche, and Next-Generation OmniPod®.* The Medtronic MiniMed® 530G pump is unchanged from the Paradigm® Revel™ pump with the exception of the added Threshold Suspend tool, and some minor software differences.

OneTouch ® Ping® was proven Dose-to-dose variability comparison of typical pump§ performance superior in accuracy in a study OneTouch ® Ping® vs. Medtronic† OneTouch ® Ping® vs. Roche OneTouch ® Ping® vs. Next-Generation OmniPod® comparing dose-to-dose variability † by pump versus Medtronic, Roche, OneTouch ® Ping® OneTouch ® Ping® OneTouch ® Ping® ® Medtronic† Roche Next-Generation OmniPod® and Next-Generation OmniPod . 40 40 120

All pumps in the study were programmed to 30 30 80 deliver a basal rate of 0.5 U/hr over 20 hours, 20 20 with the Next-Generation OmniPod® delivering 0.05 U 40 basal doses every 6 minutes while the other three 10 10

pumps delivered 0.025 U basal doses every 3 minutes. 0 0 0

Thirty data sets were assessed. In total, 5,977 -10 -10 -40 doses, 12,000 doses, 11,987 doses, and 11,947 -20 -20 % Error in Dose Volume % Error in Dose Volume doses were delivered for Next-Generation % Error in Dose Volume -80 OmniPod ®, OneTouch ® Ping®, Medtronic,† and -30 -30

Roche pumps, respectively. -40 -40 -120 0 5 10 15 20 0 5 10 15 20 0 5 10 15 20 Test Duration (hrs) Test Duration (hrs) Test Duration (hrs)

Cumulative doses within ±10% accuracy threshold for all 30 data sets 86% OneTouch ® Ping® 86% OneTouch ® Ping® 86% OneTouch ® Ping® 73% Medtronic† 76% Roche 23% Next-Generation OmniPod® P=.0009 P=.0019 P<.0001

More accurate basal delivery versus Medtronic, *Bench data: Jahn LG, Capurro JJ, Levy BL. Comparative dose accuracy of durable and patch insulin infusion pumps. J Diabetes Sci Technol. 2013;7(4):1011-1020. (Study conducted using ® OneTouch ® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®.) Capurro J, Levy B. Dose accuracy Roche, and Next-Generation OmniPod . ® ® ® ® comparison between Animas OneTouch Ping , Insulet OmniPod , and Next-Generation OmniPod . Abstract and poster presented at: Diabetes Technology Society Meeting; October 31- ® ® November 2, 2013; San Francisco, CA. In a study comparing the dose-to-dose variability of the OneTouch Ping †A combination of two Medtronic MiniMed Paradigm® Revel™ and four Veo™ pumps were assessed. The Paradigm® Veo™ pump is available for sale in select markets outside the U.S. versus Medtronic, Roche, and Next-Generation OmniPod®, OneTouch ® Ping® ‡The Medtronic MiniMed® 530G pump is unchanged from the Paradigm® Revel™ pump with the exception of the added Threshold Suspend tool, and some minor software differences. §For each manufacturer, the “typical pump” is the data set with the median standard deviation in dose percent error. was proven to deliver fewer doses that deviated from the target volume.*

P36337_OTP_DetAid_OmniPodUpdate_r12.indd 6-7 10/25/13 5:49 PM OneTouch® Ping ®. Where clinical performance meets lifestyle performance.

> Superior at reducing postprandial hyperglycemia vs. Medtronic8* > More accurate basal delivery vs. Medtronic, Roche, and Next-Generation OmniPod®† > Discreet diabetes management, outstanding readability, and carb counting accuracy > Uninterrupted insulin delivery with a pump that is proven waterproof at 12 feet for 24 hours‡

*The Medtronic MiniMed® 530G pump is unchanged from the Paradigm® Revel™ pump with the exception of the added Threshold Suspend tool, and some minor software differences. †Bench data: Jahn LG, Capurro JJ, Levy BL. Comparative dose accuracy of durable and patch insulin infusion pumps. J Diabetes Sci Technol. 2013;7(4):1011-1020. (Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®.) Capurro J, Levy B. Dose accuracy comparison between Animas OneTouch® Ping®, Insulet OmniPod®, and Next-Generation OmniPod®. Abstract and poster presented at: Diabetes Technology Society Meeting; October 31-November 2, 2013; San Francisco, CA. ‡The meter-remote must not be exposed to water.

Animas has received both ISO 13485:2003 (International Organization for Standardization) certification and The Joint Commission accreditation. By meeting these most rigorous standards, Animas is committed to superior quality Animas Corporation and safety for its customers. A Johnson & Johnson Company 200 Lawrence Drive West Chester, PA 19380 Phone: 1-877-YES-PUMP (1-877-937-7867) Email: [email protected] www.animas.com

1. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26(4):1079-1087. 2. Rudolph JW, Hirsch IB. Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. Endocr Pract. 2002;8(6):401-405. 3. Hoogma RPLM, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycemic control and quality of life: results of the 5-nations trial. Diabet Med. 2005;23(2):141-147. 4. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med. 2002;19(9):746-751. 5. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta- analysis of randomized controlled trials. BMJ. 2002;324(7739):705+. 6. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996;19(4):324-327. 7. Bode BW, Sabbah HT, Gross TM, Frederickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev. 2002;18(suppl 1):S14-S20. 8. Zisser H, Wagner R, Pleus S, et al. Clinical performance of three bolus calculators in subjects with type 1 diabetes mellitus: a head-to-head-to-head comparison. Diabetes Technol Ther. 2010;12(12):955-961. 9. Burton DM, Uslan MM, Blubaugh MV, Clements CW 3rd. Are current insulin pumps accessible to blind and visually impaired people? J Diabetes Sci Technol. 2009;3(3):613-618.

P36337_OTP_DetAid_OmniPodUpdate_r12.indd 8 10/25/13 5:49 PM